About Pardes Biosciences
Pardes Biosciences is a company based in Berkeley (United States) founded in 2020 was acquired by Foresite Capital in July 2023. Pardes Biosciences has raised $51.61 million across 1 funding round from investors including Foresite Capital. The company has 29 employees as of December 31, 2021. Pardes Biosciences operates in a competitive market with competitors including ExeVir Bio, Vaxxinity, NRx, Inimmune and IMUNON, among others.
- Headquarter Berkeley, United States
- Employees 29 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Pardes Biosciences, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$51.61 M (USD)
in 1 rounds
-
Latest Funding Round
$51.61 M (USD), Series C
Feb 03, 2021
- Investors
-
Employee Count
29
as on Dec 31, 2021
-
Acquired by
Foresite Capital
(Jul 17, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Pardes Biosciences
Unlock access to complete
Unlock access to complete
Funding Insights of Pardes Biosciences
Pardes Biosciences has successfully raised a total of $51.61M through 1 strategic funding round. The most recent funding activity was a Series C round of $51.61 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Pardes Biosciences
Pardes Biosciences has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Foresite Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Locked | Locked | Locked |
Investor details for Pardes Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Pardes Biosciences
Investment portfolio details for Pardes Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Pardes Biosciences
Detailed financials for Pardes Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Pardes Biosciences Comparisons
Peer comparison for Pardes Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Pardes Biosciences
Pardes Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ExeVir Bio, Vaxxinity, NRx, Inimmune and IMUNON, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of antibody-based therapies to monitor viral infections
|
|
| Locked | Locked | Locked |
Vaccines for neurological disorders and infectious diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for COVID-19 and neurological disorders are developed.
|
|
| Locked | Locked | Locked |
Integrated clinical developmental services to treat food allergy, allergic rhinitis, and auto-immune disorders
|
|
| Locked | Locked | Locked |
Immunotherapeutics for cancer treatment are developed using DNA-based platforms.
|
Detailed competitors of Pardes Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Pardes Biosciences
Complete news archive for Pardes Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pardes Biosciences
Pardes Biosciences was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Pardes Biosciences is headquartered in Berkeley, United States. It is registered at Berkeley, California, United States.
Pardes Biosciences is a funded company, having raised a total of $51.61M across 1 funding round to date.
As of Dec 31, 2021, the latest employee count at Pardes Biosciences is 29.
Pardes Biosciences was founded in 2020 and is based in Berkeley, United States. Focus is placed on the biotechnology sector, where therapeutics for pandemic diseases are developed. Operations center on antiviral drug candidates, with the lead product PBI-0451 serving as an oral coronaviral protease inhibitor. This compound is targeted at treating and preventing SARS-CoV-2 infections in clinical settings.
Pardes Biosciences's top competitors include NRx, ExeVir Bio and Ashvattha Therapeutics.
Pardes Biosciences has 1 investor. Key investors include Foresite Capital.